Stabilized inteferon compositions

摘要

Stabilized pharmaceutical formulations comprising IFN-beta and highly purified mannitol are provided. The highly purified mannitol stabilizes the compositions by reducing the formation of IFN-beta adducts in comparison with IFN-beta formulated with mannitol that has not been highly purified. Methods for increasing the stability of IFN-beta or a variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.